Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 5/20 | 0.66 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | VCP | P55072 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982010 | 1.00 | HPGDS (0.66) | HPGDSMAP4K4GRM5GABRA5DGAT1 | |
| SCHEMBL2982015 | 1.00 | HPGDS (0.66) | HPGDSMAP4K4GRM5GABRA5DGAT1 | |
| SCHEMBL1542953 | 0.95 | HPGDS (0.62) | HPGDSMAP4K4GRM5GABRA5DGAT1 | |
| SCHEMBL1543046 | 0.95 | HPGDS (0.62) | HPGDSMAP4K4GRM5GABRA5DGAT1 | |
| SCHEMBL1542966 | 0.95 | HPGDS (0.62) | HPGDSMAP4K4GRM5GABRA5DGAT1 | |
| SCHEMBL1543340 | 0.93 | HPGDS (0.74) | HPGDSMAP4K4GRM5GABRA5USP30 | |
| SCHEMBL1543455 | 0.91 | HPGDS (0.68) | HPGDSMAP4K4GRM5GABRA5USP30 | |
| SCHEMBL1543465 | 0.90 | HPGDS (0.70) | HPGDSMAP4K4GRM5GABRA5USP30 | |
| SCHEMBL1543463 | 0.90 | HPGDS (0.70) | HPGDSMAP4K4GRM5GABRA5USP30 | |
| SCHEMBL2988675 | 0.89 | HPGDS (0.64) | HPGDSMAP4K4GRM5GABRA5USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| US-20100173888-A1 | Nicotinamide Derivatives | PFIZER INC | 2010-07-08 | — | — | US | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173888-A1 | Nicotinamide Derivatives | NNT, NAMPT, NQO1 | HPGDS 1073/4885MAP4K4 2268/4885GRM5 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.